KabaFusion’s Acquisition of Lincare Strengthens Infusion Business

KabaFusion recently announced it has acquired the home infusion assets of Lincare, a subsidiary of Linde plc. KabaFusion is a leading provider of specialty acute and chronic home infusion therapies.

KabaFusion was acquired by Pritzker Private Capital in early 2019. Pritzker Private Capital (Pritzker) plans to invest alongside KabaFusion’s pharmacist-led management team, who continue to lead the business. KabaFusion, led by founder Dr. Sohail Masood, has been a leader in patient-focused home infusion services with deep clinical expertise in intravenous immunoglobulin (IVIG) therapies. This is KabaFusion’s first acquisition since its acquisition by Pritzker.

The acquisition of Lincare strengthens KabaFusion’s position as a leading clinician-led home infusion company, significantly enhancing the company’s ability to deliver superior patient care across a broad range of home infusion therapies nationwide.

The addition of Lincare’s infusion operations expands KabaFusion’s footprint to 28 home infusion specialty pharmacies, adding key strategic markets in Alabama, Arkansas, Florida, Indiana, Kentucky, Michigan, New Jersey, New York, North Carolina, Virginia and Wyoming.

Together with KabaFusion’s existing pharmacies in California, Florida, Illinois, Massachusetts, New Jersey, Pennsylvania and Texas, the company is licensed to serve patients in 44 states with a comprehensive offering of acute, chronic and enteral therapies.

KabaFusion recently established a new eastern headquarters location in Lexington, MA. The company is increasing its space in a move from Waltham, MA.


Takeaway: KabaFusion its strengthening its position as a national home infusion leader.